Granulomatous Disease, Chronic, X-linked Clinical Trial
Official title:
A Two-Part, Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
Chronic Granulomatous Disease (CGD) is an inherited immunodeficiency disorder which results from defects that prevent white blood cells from effectively killing bacteria, fungi and other microorganisms. Chronic granulomatous inflammation may compromise vital organs and account for additional morbidity. CGD is thought to affect approximately 1 in 200,000 persons, although the real incidence might be higher due to under-diagnosis of milder phenotypes. The first gene therapy approaches in X-CGD have shown that effective gene therapy requires bone-marrow (BM) conditioning with chemotherapy to make space for the gene-modified cells to engraft. These studies demonstrated that transplantation of gene modified stem cells led to production of white blood cells that could clear existing infections. However, some trials using mouse-derived retroviral vectors were complicated by the development of myelodysplasia and leukemia-like growth of blood cells. This trial will evaluate a new lentiviral vector that may be able to correct the defect, but have much lower risk for the complication. This study is a two-part, prospective non-controlled, non-randomized Phase I/II clinical trial to assess the safety, feasibility and efficacy of cellular gene therapy in patients with chronic granulomatous disease using transplantation of autologous bone marrow CD34+ cells transduced ex vivo by the G1XCGD lentiviral vector containing the human CGD gene. Primary objectives include evaluation of safety and evaluation of efficacy by biochemical and functional reconstitution in progeny of engrafted cells and stability at 12 months. Secondary objectives include evaluation of clinical efficacy, longitudinal evaluation of clinical effect in terms of augmented immunity against bacterial and fungal infection, transduction of CD34+ hematopoietic cells from X-CGD patients by ex vivo lentivirus-mediated gene transfer, and evaluation of engraftment kinetics and stability. Approximately 3-6 patients will be treated per site with a goal of 16 total patients to be treated with G1XCGD lentiviral vector.
| Status | Recruiting |
| Enrollment | 16 |
| Est. completion date | December 2028 |
| Est. primary completion date | December 2026 |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | 23 Months and older |
| Eligibility | Inclusion Criteria: (Part A & B) - Male X-CGD patients > 23 months of age - Molecular diagnosis confirmed by DNA sequencing and supported by laboratory evidence for absent or reduction > 95% of the biochemical activity of the NADPH-oxidase - At least one prior, ongoing or refractory severe infection and/or inflammatory complications requiring hospitalization despite conventional therapy - No 10/10 HLA-matched donor available after initial search of NMDP registries - No co-infection with Human Immunodeficiency Virus (HIV)-1 or -2, hepatitis B virus or hepatitis C virus, adenovirus, parvovirus B 19 or toxoplasmosis, or active infection with CMV - Written informed consent for adult patient, and assent for pediatric subjects seven years or older. - Parental/guardian and, where appropriate, child's signed consent/assent Exclusion Criteria: - Age < 23 months - 10/10 HLA identical (A,B,C,DR,DQ) family or unrelated or cord blood donor unless there is deemed to be an unacceptable risk associated with an allogeneic procedure - Contraindication for leukapheresis or bone marrow harvest (anemia Hb <8g/dl, cardiovascular instability, severe coagulopathy) - Appropriate organ function as outlined below must be observed within 8 weeks of entering this trial. 1. Hematologic 1. Anemia (hemoglobin < 8 g/dL). 2. Neutropenia (absolute granulocyte count <1,000/mm3) 3. Thrombocytopenia (platelet count < 150,000/mm3). 4. PT or PTT > 2X the upper limits of normal (patients with a correctable deficiency controlled on medication will not be excluded). 5. Cytogenetic abnormalities known to be associated with hematopoietic defect on peripheral blood or bone marrow. 2. Infectious a. Evidence of co-infection with HIV-1, HIV-2, hepatitis B, Hepatitis C, adenovirus, parvovirus B19, toxoplasmosis. CMV infection is allowable as long as the infection is under control. 3. Pulmonary a. Resting O2 saturation by pulse oximetry < 90% on room air. 4. Cardiac 1. Abnormal electrocardiogram (EKG) indicating cardiac pathology. 2. Uncorrected congenital cardiac malformation with clinical symptomatology. 3. Active cardiac disease, including clinical evidence of congestive heart failure, cyanosis, hypotension. 4. Poor cardiac function as evidenced by LV ejection fraction < 40% on echocardiogram. 5. Neurologic 1. Significant neurologic abnormality by examination. 2. Uncontrolled seizure disorder. 6. Renal 1. Renal insufficiency: serum creatinine = 1.5 mg/dl, or = 3+ proteinuria. 2. Abnormal serum sodium, potassium, calcium, magnesium, phosphate at grade III or IV by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 7. Hepatic/GI: 1. Serum transaminases > 5X the upper limit of normal (ULN). 2. Serum bilirubin > 2X ULN. 3. Serum glucose > 1.5x ULN. 8. Oncologic a. Evidence of active malignant disease 9. General 1. Expected survival < 6 months 2. Major congenital anomaly 3. Ineligible for autologous HSCT by the criteria at the clinical site. 4. Contraindication for administration of conditioning medication. (Known sensitivity to Busulfan) 5. Administration of gamma-interferon within 30 days before the infusion of transduced, autologous CD34+ cells. 6. Participation in another experimental therapeutic protocol within 6 months prior to baseline and during the study period. 7. Tested positive (definitive) for the presence of multiple types (2 or more) of anti-platelet antibodies. 8. Any other condition that, in the opinion of the Investigator, may compromise the safety or compliance of the patient or would preclude the patient from successful study completion. 9. Patient/Parent/Guardian unable or unwilling to comply with the protocol requirements. Part B Additional exclusion criteria: - Patients >12 years of age at enrolment - Patients =12 years of age with a body weight >40kg at enrolment |
| Country | Name | City | State |
|---|---|---|---|
| United States | National Institutes of Health | Bethesda | Maryland |
| United States | Children's Hospital Boston | Boston | Massachusetts |
| United States | University of California, Los Angeles (UCLA) | Los Angeles | California |
| Lead Sponsor | Collaborator |
|---|---|
| University of California, Los Angeles | Boston Children's Hospital, California Institute for Regenerative Medicine (CIRM), Genethon, National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Santilli G, Almarza E, Brendel C, Choi U, Beilin C, Blundell MP, Haria S, Parsley KL, Kinnon C, Malech HL, Bueren JA, Grez M, Thrasher AJ. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther. 2011 Jan;19(1):122-32. doi: 10.1038/mt.2010.226. Epub 2010 Oct 26. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Concentration of gp91 protein produced in response to the corrected gene | We will look for the presence of gp91 antibodies in blood | up to 2 years | |
| Other | Characterization of drug product immunophenotype | Different lymphocyte subsets using flow cytometry | up to 2 years | |
| Primary | The incidence of adverse events assessed by CTCAE v4 | Record clinical significant adverse events, laboratory abnormalities, monitor overall adverse events for the study as a whole, including serious adverse events | up to 2 years | |
| Primary | Measuring percentage of subjects who have = 10% oxidase positive granulocytes | Oxidase positive granulocytes for each subject will be assessed by DHR flow cytometry | At month 12 after transplant |